Toxicities associated with adoptive t-cell transfer for cancer

Cancer Journal (United States)

Volumn 21, Issue 6, 2015, Pages 506-509

  Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute cytokine release; Autoimmune complications; Cancer; Cultured immune cells; Infection; Off target toxicities; Toxicities

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; PROTEOME; RECOMBINANT INTERLEUKIN 2; TOCILIZUMAB; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL CULTURE; CELL TRANSFER; CORTICOSTEROID THERAPY; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFICACY; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MONOTHERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; TUMOR REGRESSION; WART VIRUS; IMMUNOLOGY; NEOPLASMS;

HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84948429019     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000157     Document Type: Review

References (33)

1. + T cells via TLR4 signaling. J Clin Invest. 2007; 117: 2197-2204.
2. + T helper cells and hindered by naturally occurring T regulatory cells. J Ismmunol. 2005; 174: 2591-2601.
3. Klebanoff CA, KhongHT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005; 26: 111-117.
4. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-854.
5. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26: 5233-5239.
6. +-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013; 31: 2152-2159.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl JMed. 2013; 368: 1509-1518.
8. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24: 2283-2289.
9. Straathof KC, Spencer DM, Sutton RE, et al. Suicide genes as safety switches in T lymphocytes. Cytotherapy. 2003; 5: 227-230.
10. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114: 535-546.
11. Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009; 116: 981-989.
12. Seaman BJ, Guardiani EA, Brewer CC, et al. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 2012; 147: 744-749.
13. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013; 21: 904-912.
14. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24: e20-e22.
15. ParkhurstMR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19: 620-626.
16. Brentjens RJ, DavilaML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5: 177ra38.
17. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709-2720.
18. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68: 2961-2971.
19. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl JMed. 2011; 365: 725-733.
20. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015; 33: 540-549.
21. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36: 133-151.
22. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and Titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122: 863-871.
23. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013; 5: 197ra103.
24. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010; 16: 565-570.
25. Bunse M, Bendle GM, Linnemann C, et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther. 2014; 22: 1983-1991.
26. Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012; 18: 807-815.
27. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007; 109: 2331-2338.
28. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557.
29. Chen YT, Boyer AD, Viars CS, et al. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet. 1997; 79: 237-240.
30. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: longterm follow-up and correlates with response. Clin Cancer Res. 2015; 21: 1019-1027.
31. Stevanovic S, Draper LM, LanghanMM, et al. Complete regression ofmetastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015; 33: 1543-1550.
32. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumorreactive T cells. Nat Med. 2013; 19: 747-752.
33. + T cells in a patient with epithelial cancer. Science. 2014; 344: 641-645.